标题
Membranoproliferative Glomerulonephritis und C3‑Glomerulopathie
作者
关键词
Proteine des Komplementsystems, Medizinische Genetik, „Dense deposit disease“, C3-Glomerulonephritis, Mit KomplementfaktorH verwandte Proteine (CFHR), Complement system proteins, Genetics, medical, „Dense deposit disease“, C3Glomerulonephritis, „Complement factorH-related proteins“ (CFHR)
出版物
INTERNIST
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2019-03-12
DOI
10.1007/s00108-019-0572-0
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy
- (2018) Rupali S. Avasare et al. Clinical Journal of the American Society of Nephrology
- Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy
- (2018) Marina Noris et al. PEDIATRIC NEPHROLOGY
- Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex–Mediated Membranoproliferative GN
- (2017) Paraskevas Iatropoulos et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- C5 nephritic factors drive the biological phenotype of C3 glomerulopathies
- (2017) Maria-Chiara Marinozzi et al. KIDNEY INTERNATIONAL
- Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
- (2017) Timothy H.J. Goodship et al. KIDNEY INTERNATIONAL
- Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies
- (2017) Michael Rudnicki Biomed Research International
- Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome
- (2016) Paraskevas Iatropoulos et al. MOLECULAR IMMUNOLOGY
- New milestones ahead in complement-targeted therapy
- (2016) Daniel Ricklin et al. SEMINARS IN IMMUNOLOGY
- Remission of C3 glomerulopathy with rituximab as only immunosuppressive therapy
- (2015) Philippe Giaime et al. CLINICAL NEPHROLOGY
- Effectiveness of mycophenolate mofetil in C3 glomerulonephritis
- (2015) Cristina Rabasco et al. KIDNEY INTERNATIONAL
- Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome
- (2014) Mihály Józsi et al. IMMUNOLOGY LETTERS
- Histopathology of MPGN and C3 glomerulopathies
- (2014) H. Terence Cook et al. Nature Reviews Nephrology
- Rituximab fails where eculizumab restores renal function in C3nef-related DDD
- (2014) Caroline Rousset-Rouvière et al. PEDIATRIC NEPHROLOGY
- Treatment of C3 Glomerulopathy with Complement Blockers
- (2014) Francesco Emma et al. SEMINARS IN THROMBOSIS AND HEMOSTASIS
- C3 glomerulopathy–associated CFHR1 mutation alters FHR oligomerization and complement regulation
- (2013) Agustín Tortajada et al. JOURNAL OF CLINICAL INVESTIGATION
- C3 glomerulopathy: consensus report
- (2013) Matthew C. Pickering et al. KIDNEY INTERNATIONAL
- Toward a working definition of C3 glomerulopathy by immunofluorescence
- (2013) Jean Hou et al. KIDNEY INTERNATIONAL
- Complement factor H related proteins (CFHRs)
- (2013) Christine Skerka et al. MOLECULAR IMMUNOLOGY
- The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment
- (2012) A. M. Risitano et al. BLOOD
- Combination of Factor H Mutation and Properdin Deficiency Causes Severe C3 Glomerulonephritis
- (2012) A. M. Lesher et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
- (2012) Julien Zuber et al. Nature Reviews Nephrology
- C3 glomerulopathy: a new classification
- (2010) Fadi Fakhouri et al. Nature Reviews Nephrology
- Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway
- (2009) Sanjeev Sethi et al. KIDNEY INTERNATIONAL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More